$SUPN insider trading
Over the last 12 months, Supernus Pharmaceuticals insiders reported no purchases and 22 sales totaling $24.5M across SEC Form 4 filings. 73% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $24.5M 22 events
- Events · 12m
- 22 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 73% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Bhatt Padmanabh P.Sr. VP of IP, CSO · O | ▼ Sale | 107,250 | $50.24 | $5.4M | -86.3% | plan · 6 tranches |
| Mar 13, 2026 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 35,000 | $50.37 | $1.8M | -3.5% | plan · 3 tranches · indirect |
| Mar 12, 2026 | Hudson Frederick M.D | ▼ Sale | 5,369 | $50.61 | $272K | -8.2% | — |
| Mar 10, 2026 | Horich William ToddSVP, Commercial Operations · O | ▼ Sale | 8,877 | $54.5 | $484K | -100% | 2 tranches |
| Mar 9, 2026 | Mottola FrankSVP, Chief Tech. Ops. Officer · O | ▼ Sale | 1,623 | $53.65 | $87K | -8.1% | — |
| Mar 6, 2026 | GEMAYEL GEORGESD | ▼ Sale | 18,787 | $53.38 | $1.0M | -40.8% | 2 tranches |
| Feb 19, 2026 | Sensenig BethanyD | ▼ Sale | 4,475 | $51.01 | $228K | -100% | plan · 2 tranches |
| Dec 19, 2025 | Mottola FrankSVP, Chief Tech. Ops. Officer · O | ▼ Sale | 20,000 | $50.41 | $1.0M | -56.3% | plan · 2 tranches |
| Dec 18, 2025 | Bhatt Padmanabh P.Sr. VP of IP, CSO · O | ▼ Sale | 710 | $44.44 | $32K | -4.7% | — |
| Oct 9, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 59,900 | $50.57 | $3.0M | -4.7% | plan · 2 tranches |
| Oct 9, 2025 | NEWHALL CHARLES W IIID | ▼ Sale | 25,000 | $50.77 | $1.3M | -19.3% | plan · 2 tranches |
| Oct 2, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 1,904 | $48.06 | $92K | -0.2% | plan |
| Oct 1, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 40,173 | $48.07 | $1.9M | -3.3% | plan |
| Sep 30, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 8,588 | $48.25 | $414K | -0.7% | plan |
| Sep 29, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 10,235 | $48.02 | $491K | -0.9% | plan |
| Sep 23, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 29,513 | $47.23 | $1.4M | -2.5% | plan |
| Sep 22, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 16,587 | $47.02 | $780K | -1.5% | plan |
| Sep 12, 2025 | Mottola FrankSVP, Chief Tech. Ops. Officer · O | ▼ Sale | 5,000 | $45.87 | $229K | -24.4% | — |
| Sep 8, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 6,322 | $46.29 | $293K | -0.6% | plan |
| Sep 5, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 55,578 | $46.01 | $2.6M | -4.8% | plan |
| Aug 28, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 34,800 | $45.1 | $1.6M | -3.1% | plan · 2 tranches |
| Aug 27, 2025 | NEWHALL CHARLES W IIID | ▼ Sale | 3,588 | $45.01 | $161K | -2.7% | plan |
| Aug 25, 2025 | Mottola FrankSVP, Quality, GMP, Ops, IT · O | ▼ Sale | 14,000 | $44.51 | $623K | -47.5% | — |
| Aug 25, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 1,000 | $45 | $45K | -0.1% | plan |
| Aug 25, 2025 | NEWHALL CHARLES W IIID | ▼ Sale | 1,000 | $45 | $45K | -0.7% | plan |
| Aug 22, 2025 | Khattar Jack A.President, CEO · O·D | ▼ Sale | 1,500 | $45 | $68K | -0.1% | plan |
| Aug 22, 2025 | DEC TIMOTHY CSenior Vice-President & CFO · O | ▼ Sale | 11,780 | $44.49 | $524K | -90.4% | — |
| Aug 22, 2025 | NEWHALL CHARLES W IIID | ▼ Sale | 1,412 | $45 | $64K | -1% | plan |
| Aug 14, 2025 | Sensenig BethanyD | ▼ Sale | 5,369 | $42.25 | $227K | -100% | plan |
| Aug 14, 2025 | Hudson Frederick M.D | ▼ Sale | 7,457 | $42.26 | $315K | -13.9% | — |
Every $SUPN filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Supernus Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SUPN feed.